Barclays’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
– Sell
-50,000
Closed -$4.48M – 7229
2018
Q2
$4.48M Buy
+50,000
New +$4.22M ﹤0.01% 1812

Other funds holding HAE

Barclays's HAE Position: Q3 2026 in Review

Barclays increased its Haemonetics (HAE) stake by 98% in Q3 2026, buying an estimated $3.3M and bringing the position to 71,684 shares worth $7.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1815.

Barclays first reported a position in HAE in Q2 2013 and has held it in 54 quarters since. The position peaked at $16.4M in Q2 2025. 361 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • Barclays held 71,684 shares of Haemonetics worth $7.55M as of Q3 2026.
  • Barclays bought 35,485 Haemonetics shares in Q3 2026, an estimated $3.3M.
  • Haemonetics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1815 holding.
  • Barclays first reported a position in Haemonetics in Q2 2013 and has held it in 54 quarters since.
  • Barclays's Haemonetics position peaked at $16.4M in Q2 2025.
  • 361 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.